The estimated Net Worth of John L. Magnani is at least $1.67 Million dollars as of 11 November 2022. John Magnani owns over 45,045 units of GlycoMimetics Inc stock worth over $58,572 and over the last 11 years he sold GLYC stock worth over $353,767. In addition, he makes $1,255,450 as Co-Founder, Senior Vice President und Chief Scientific Officer at GlycoMimetics Inc.
Sign up
John Magnani GLYC stock SEC Form 4 insiders trading
John has made over 7 trades of the GlycoMimetics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 45,045 units of GLYC stock worth $52,703 on 11 November 2022.
The largest trade he's ever made was exercising 106,984 units of GlycoMimetics Inc stock on 20 December 2019 worth over $119,822. On average, John trades about 17,509 units every 118 days since 2014. As of 11 November 2022 he still owns at least 366,078 units of GlycoMimetics Inc stock.
You can see the complete history of John Magnani stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John Magnani biography
Dr. John Magnani Ph.D. serves as Co-Founder, Senior Vice President, Chief Scientific Officer of the Company. Dr. Magnani is a co-founder of our company and has served as our Senior Vice President of Research since January 2017, as our Vice President of Research from 2003 to 2017 and as our Chief Scientific Officer since 2003. He has served as a member of our Board since our inception in 2003, and his term as a director will end in May 2019 upon the conclusion of the annual meeting. Dr. Magnani is also the founder, President and owner of GlycoTech Corporation. Prior to founding GlycoTech, Dr. Magnani was the Vice President of Research at BioCarb, Inc., one of the first glycobiology-based companies. Earlier in his career, Dr. Magnani was a tenured Research Chemist at the National Institute of Arthritis, Diabetes and Digestive and Kidney Diseases, part of the National Institutes of Health. Dr. Magnani received an A.B. from Washington University in St. Louis and a Ph.D. in biology from Princeton University.
What is the salary of John Magnani?
As the Co-Founder, Senior Vice President und Chief Scientific Officer of GlycoMimetics Inc, the total compensation of John Magnani at GlycoMimetics Inc is $1,255,450. There are 3 executives at GlycoMimetics Inc getting paid more, with Rachel King having the highest compensation of $2,689,070.
How old is John Magnani?
John Magnani is 67, he's been the Co-Founder, Senior Vice President und Chief Scientific Officer of GlycoMimetics Inc since 2019. There are 1 older and 13 younger executives at GlycoMimetics Inc. The oldest executive at GlycoMimetics Inc is Dr. John L. Magnani, 68, who is the Sr. VP of Research & Chief Scientific Officer.
What's John Magnani's mailing address?
John's mailing address filed with the SEC is C/O GLYCOMIMETICS, INC., 9708 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850.
Insiders trading at GlycoMimetics Inc
Over the last 11 years, insiders at GlycoMimetics Inc have traded over $15,299,593 worth of GlycoMimetics Inc stock and bought 10,868,557 units worth $48,421,008 . The most active insiders traders include Scott D Sandell, Peter J Barris und M James Barrett. On average, GlycoMimetics Inc executives and independent directors trade stock every 51 days with the average trade being worth of $38,210. The most recent stock trade was executed by Public Equities, L.P.Invus ... on 7 August 2024, trading 322,361 units of GLYC stock currently worth $61,249.
What does GlycoMimetics Inc do?
at glycomimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow’s breakthrough treatments. glycomimetics is a clinical-stage biotechnology company. we use novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. since the company’s inception in 2003, we have developed a robust, diversified product pipeline. we are a public company traded on the nasdaq under the symbol glyc.
What does GlycoMimetics Inc's logo look like?
Complete history of John Magnani stock trades at GlycoMimetics Inc
GlycoMimetics Inc executives and stock owners
GlycoMimetics Inc executives and other stock owners filed with the SEC include:
-
Rachel King,
President, Chief Executive Officer, Co-Founder, Director -
Brian Hahn,
Chief Financial Officer -
Helen Thackray,
Senior Vice President - Clinical Development, Chief Medical Officer -
John Magnani,
Co-Founder, Senior Vice President, Chief Scientific Officer -
Rachel K. King,
Pres, CEO & Director -
Brian M. Hahn,
Sr. VP & CFO -
Timothy Pearson,
Independent Chairman of the Board -
Daniel Junius,
Independent Director -
Mark Goldberg,
Independent Director -
Scott Jackson,
Independent Director -
Patricia Andrews,
Independent Director -
Scott Koenig,
Independent Director -
Armand Girard,
Senior Vice President, Chief Business Officer -
Bruce Johnson,
Sr. VP & Chief Commercial Officer -
Armand Girard,
Chief Bus. Officer and Sr. VP of Strategy & Corp. Devel. -
Dr. John L. Magnani,
Sr. VP of Research & Chief Scientific Officer -
Harout Semerjian,
CEO, Pres & Director -
Dr. Eric J. Feldman M.D.,
Sr. VP & Chief Medical Officer -
Christian Dinneen-Long,
VP, Corp. Counsel & Corp. Sec. -
Henry Flanner,
VP of Technical Operations -
Stephanie R. Irish,
VP of Accounting -
Partners L P/Ilbiotechnolog...,
-
Scott D Sandell,
10% owner -
Franklin H Jr Top,
Director -
Peter J Barris,
10% owner -
Michael A Henos,
Director -
M James Barrett,
Director -
Enterprise Associates 10 L ...,
-
John J. Baldwin,
Director -
Chinmaya Rath,
SVP and Chief Business Officer -
William M. Gust,
Director -
Enterprise Associates 13 Lp...,
-
Partners L P/Ilbiotechnolog...,
-
Harout Semerjian,
Chief Executive Officer -
Public Equities, L.P.Artal ...,
-
Public Equities, L.P.Invus ...,
-
Bruce S Johnson,
SVP & Chief Commercial Officer -
Edwin Rock,
Chief Medical Officer